You are here
This study is looking at a type of treatment called intestinal microbiota transplant. It’s a way of encouraging more variety in gut bacteria.
This trial is comparing standard treatment with 2 newer combinations of treatment to prevent GvHD.
This trial was for people with chronic myeloid leukaemia. It looked at adding a targeted drug to the targeted drug people were already taking.
Leukaemia is the most common cause of young people’s cancer death.
Mortality rates for chronic myeloid leukaemia in the UK are highest in people aged 90+ (2017-2019).
Each year around two-thirds of all chronic myeloid leukaemia deaths (67%) in the UK are in people aged 75 and over (2017-2019).
This study is comparing a new drug called asciminib with bosutinib for chronic myeloid leukaemia (CML).
Since the early 1970s, chronic myeloid leukaemia mortality rates have decreased by almost three-quarters (73%) in the UK. Rates in females have decreased by almost four-fifths (78%), and rates in males have decreased by around seven-tenths (71%) (2017-2019).
Over the last decade, chronic myeloid leukaemia mortality rates have decreased by around a seventh (15%) in the UK. Rates in females have decreased by more than a fifth (22%), and rates in males have remained stable (2017-2019).
Brain, other CNS and intracranial tumours are the most common cause of young people's cancer death.
Mortality rates for chronic myeloid leukaemia in the UK are highest in people aged 90+ (2014-2016).
Since the early 1990s, chronic myeloid leukaemia incidence rates have decreased by around a quarter (26%) in the UK. Rates in females have decreased by a fifth (20%), and rates in males have decreased by more than a third (35%) (2017-2019).
Over the last decade, chronic myeloid leukaemia incidence rates have remained stable in the UK. Rates in females have increased by almost a sixth (16%), and rates in males have remained stable (2017-2019).
